The President – Global A & M A of Omnicell, Inc. (OMCL), Robin Seim Unloaded 13,286 Shares; Deerfield Management Company Increased Agios Pharmaceuticals (AGIO) Holding

May 17, 2018 - By David Stenberg

Omnicell, Inc. (NASDAQ:OMCL) Logo

Deerfield Management Company increased Agios Pharmaceuticals Inc (AGIO) stake by 26.43% reported in 2017Q4 SEC filing. Deerfield Management Company acquired 54,984 shares as Agios Pharmaceuticals Inc (AGIO)’s stock rose 38.11%. The Deerfield Management Company holds 262,984 shares with $15.04M value, up from 208,000 last quarter. Agios Pharmaceuticals Inc now has $4.97B valuation. The stock increased 0.89% or $0.76 during the last trading session, reaching $86.2. About 238,655 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 41.40% since May 17, 2017 and is uptrending. It has outperformed by 29.85% the S&P500.

Analysts await Omnicell, Inc. (NASDAQ:OMCL) to report earnings on July, 26. They expect $0.25 earnings per share, up 1,150.00% or $0.23 from last year’s $0.02 per share. OMCL’s profit will be $9.72 million for 46.05 P/E if the $0.25 EPS becomes a reality. After $0.16 actual earnings per share reported by Omnicell, Inc. for the previous quarter, Wall Street now forecasts 56.25% EPS growth.

The stock decreased 1.18% or $0.55 during the last trading session, reaching $46.05. About 309,666 shares traded or 14.68% up from the average. Omnicell, Inc. (NASDAQ:OMCL) has risen 5.20% since May 17, 2017 and is uptrending. It has underperformed by 6.35% the S&P500.

Since December 15, 2017, it had 0 insider buys, and 7 insider sales for $1.81 million activity. JOHNSTON DAN S sold 11,284 shares worth $507,248. $617,524 worth of Omnicell, Inc. (NASDAQ:OMCL) shares were sold by Seim Robin Gene. On Thursday, March 15 the insider PETERSMEYER GARY S sold $25,544. 3,456 shares were sold by Kuipers Peter J., worth $164,562. 8,186 shares were sold by LIPPS RANDALL A, worth $361,938.

Among 10 analysts covering Omnicell (NASDAQ:OMCL), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Omnicell has $63.0 highest and $33.0 lowest target. $48.22’s average target is 4.71% above currents $46.05 stock price. Omnicell had 28 analyst reports since July 31, 2015 according to SRatingsIntel. On Tuesday, December 5 the stock rating was maintained by Oppenheimer with “Buy”. Cantor Fitzgerald maintained it with “Buy” rating and $63.0 target in Thursday, February 1 report. The stock of Omnicell, Inc. (NASDAQ:OMCL) earned “Buy” rating by Oppenheimer on Monday, January 29. The stock of Omnicell, Inc. (NASDAQ:OMCL) earned “Buy” rating by Oppenheimer on Friday, July 28. Cantor Fitzgerald maintained Omnicell, Inc. (NASDAQ:OMCL) on Tuesday, July 25 with “Buy” rating. The firm earned “Hold” rating on Friday, February 2 by Craig Hallum. Craig Hallum maintained it with “Buy” rating and $62.0 target in Monday, October 30 report. As per Friday, February 2, the company rating was maintained by PiperJaffray. The firm has “Buy” rating by Cantor Fitzgerald given on Tuesday, December 5. The rating was initiated by Benchmark on Thursday, January 7 with “Buy”.

Today, an insider trading sale was made. Robin Seim, the President – Global A & M A and an insider of Omnicell Inc sold precisely 13,286 shares of Omnicell Inc, worth around $617,524 U.S Dollars, at $46.5 of a share at the time of the sale. Robin Seim at present possess 0.19% of Omnicell Inc’s market capitalization with ownership of 74,121 shares. 

Investors sentiment increased to 1.12 in 2017 Q4. Its up 0.10, from 1.02 in 2017Q3. It is positive, as 14 investors sold Omnicell, Inc. shares while 72 reduced holdings. 27 funds opened positions while 69 raised stakes. 37.38 million shares or 0.77% more from 37.10 million shares in 2017Q3 were reported. First Light Asset Limited Liability Corporation owns 317,331 shares. Federated Investors Incorporated Pa owns 449 shares. Tiaa Cref Inv Management Limited Liability holds 0% of its portfolio in Omnicell, Inc. (NASDAQ:OMCL) for 138,245 shares. Rockefeller Svcs holds 0.36% of its portfolio in Omnicell, Inc. (NASDAQ:OMCL) for 469,672 shares. Parkside State Bank And Tru holds 21 shares. Fort Washington Investment Advsr Oh reported 287,249 shares. Thomson Horstmann Bryant accumulated 115,826 shares or 0.74% of the stock. Advisory Rech has invested 0.03% of its portfolio in Omnicell, Inc. (NASDAQ:OMCL). The New York-based Bnp Paribas Arbitrage has invested 0% in Omnicell, Inc. (NASDAQ:OMCL). Parallax Volatility Advisers Limited Partnership, California-based fund reported 5,628 shares. Oak Ridge Ltd Llc reported 1.74% stake. Segall Bryant Hamill Limited Liability owns 81,778 shares. Ohio-based Stratos Wealth Partners Limited has invested 0% in Omnicell, Inc. (NASDAQ:OMCL). Pinebridge Invs Limited Partnership, New York-based fund reported 13,581 shares. D E Shaw And Co reported 18,338 shares stake.

More recent Omnicell, Inc. (NASDAQ:OMCL) news were published by: Seekingalpha.com which released: “Omnicell’s (OMCL) CEO Randall Lipps on Q1 2018 Results – Earnings Call Transcript” on April 27, 2018. Also Prnewswire.com published the news titled: “Omnicell Announces First Quarter 2018 Results” on April 26, 2018. Prnewswire.com‘s news article titled: “Sentara RMH Medical Center Partners with Omnicell to Enhance Efficiency, Safety in Central Pharmacy Operations” with publication date: May 10, 2018 was also an interesting one.

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company has market cap of $1.79 billion. The firm operates through two divisions, Automation and Analytics, and Medication Adherence. It has a 86.89 P/E ratio. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Savvy Mobile Medication Workstation, which provides a platform for hospital information systems.

Since January 10, 2018, it had 1 insider buy, and 23 selling transactions for $18.55 million activity. Alenson Carman had sold 2,150 shares worth $161,250 on Friday, January 12. 6,800 shares valued at $557,396 were sold by Foster-Cheek Kaye I on Monday, March 19. $161,192 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares were sold by Hoerter Steven L.. The insider Biller Scott sold $225,607. Bowden Christopher sold $155,305 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Friday, February 16. The insider Schenkein David P sold $3.88 million. Scadden David bought $16,688 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Friday, March 16.

Deerfield Management Company decreased Audentes Therapeutics Inc stake by 334,894 shares to 1.19 million valued at $37.20 million in 2017Q4. It also reduced Ardelyx Inc (NASDAQ:ARDX) stake by 276,900 shares and now owns 2.47M shares. Akari Therapeutics Plc was reduced too.

Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals had 45 analyst reports since July 23, 2015 according to SRatingsIntel. Credit Suisse maintained it with “Outperform” rating and $70 target in Wednesday, May 18 report. The firm has “Outperform” rating given on Wednesday, April 11 by Credit Suisse. The firm has “Buy” rating by Credit Suisse given on Thursday, February 15. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) earned “Outperform” rating by Credit Suisse on Thursday, January 21. RBC Capital Markets maintained the shares of AGIO in report on Wednesday, November 1 with “Buy” rating. The rating was downgraded by Janney Capital on Monday, June 26 to “Neutral”. The rating was maintained by Canaccord Genuity on Friday, August 7 with “Hold”. Oppenheimer maintained it with “Buy” rating and $7500 target in Tuesday, August 1 report. Oppenheimer maintained Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Thursday, June 1 with “Buy” rating. The firm has “Outperform” rating by Oppenheimer given on Tuesday, January 17.

More notable recent Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) news were published by: Nasdaq.com which released: “Agios to Present New Clinical Data from its IDH Programs at ASCO” on May 16, 2018, also Seekingalpha.com with their article: “Agios Pharmaceuticals (AGIO) Investor Presentation – Slideshow” published on May 04, 2018, Seekingalpha.com published: “Agios Pharmaceuticals’ (AGIO) CEO David Schenkein on Investor Day 2018 Results – Earnings Call Transcript” on May 06, 2018. More interesting news about Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) were released by: Streetinsider.com and their article: “Omega’s 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More…)” published on May 15, 2018 as well as Seekingalpha.com‘s news article titled: “A Fresh Look At Celgene After Q1 And New Info On Ozanimod” with publication date: May 08, 2018.

Omnicell, Inc. (NASDAQ:OMCL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 David Stenberg

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: